Benefit-risk assessment conceptual framework for exposure to biologics during pregnancy

被引：0
|
作者：
Bozzi, Laura [1 ]
Jacobson, Melanie H. [2 ]
Yost, Emily [3 ]
Cafone, Joseph [1 ]
Sheahan, Anna [4 ]
Levitan, Bennett S. [1 ]
Nelson, Robert M. [5 ]
机构：
[1] Janssen Pharmaceut, Beerse, Belgium
[2] Janssen Res & Dev, Raritan, NJ USA
[3] Janssen, Beerse, Belgium
[4] Janssen Res & Dev LLC, Raritan, NJ USA
[5] Johnson & Johnson, New Brunswick, NJ USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1124
引用
收藏
页码：529 / 529
页数：1
相关论文
共 50 条
  • [31] On a Stepwise Quantitative Approach for Benefit-Risk Assessment
    He, Weili
    Sun, Yaxuan
    Li, Qing
    Wan, Sabrina
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (05) : 625 - 634
  • [32] Benefit-Risk Assessment of Orlistat in the Treatment of Obesity
    Sumithran, Priya
    Proietto, Joseph
    DRUG SAFETY, 2014, 37 (08) : 597 - 608
  • [33] A Benefit-Risk Assessment of Sibutramine in the Management of Obesity
    Enzo Nisoli
    Michele O. Carruba
    Drug Safety, 2003, 26 : 1027 - 1048
  • [34] Benefit-risk assessment of vitamin D supplementation
    Bischoff-Ferrari, H. A.
    Shao, A.
    Dawson-Hughes, B.
    Hathcock, J.
    Giovannucci, E.
    Willett, W. C.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (07) : 1121 - 1132
  • [35] A Benefit-Risk Assessment of Basiliximab in Renal Transplantation
    Ugo Boggi
    Romano Danesi
    Fabio Vistoli
    Marco Del Chiaro
    Stefano Signori
    Piero Marchetti
    Mario Del Tacca
    Franco Mosca
    Drug Safety, 2004, 27 : 91 - 106
  • [36] A benefit-risk assessment of sibutramine in the management of obesity
    Nisoli, E
    Carruba, MO
    DRUG SAFETY, 2003, 26 (14) : 1027 - 1048
  • [37] Benefit-risk assessment: to quantify or not to quantify, that is the question
    Yuan, Zhong
    Levitan, Bennett
    Berlin, Jesse A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (06) : 653 - 656
  • [38] A benefit-risk assessment of caffeine as an analgesic adjuvant
    Zhang, WY
    DRUG SAFETY, 2001, 24 (15) : 1127 - 1142
  • [39] Benefit-risk assessment of raloxifene in postmenopausal osteoporosis
    Cranney, A
    Adachi, JD
    DRUG SAFETY, 2005, 28 (08) : 721 - 730
  • [40] On a Stepwise Quantitative Approach for Benefit-Risk Assessment
    Weili He
    Yaxuan Sun
    Qing Li
    Sabrina Wan
    Therapeutic Innovation & Regulatory Science, 2017, 51 : 625 - 634
12345